• Company
• Pharmaceutical exports continue to be sluggish...
• by Kim, Jin-Gu Mar 20, 2023 05:51am

• Policy
• Lansoprazole+antacid combo awaits entry into market
• by Lee, Tak-Sun Mar 20, 2023 05:51am

• Company
• Leclaza costs 88 billion won for phase 3 in 3 years
• by Chon, Seung-Hyun Mar 20, 2023 05:51am

• Company
• Possibility of passing the drug price reduction Act
• by Kim, Jin-Gu Mar 20, 2023 05:51am

• Company
• Generics for Visanne grew significantly in Bayer's opening
• by Whang, byung-woo Mar 17, 2023 05:46am

• Company
• Sales in the Dutasteride market are strong
• by Kim, Jin-Gu Mar 17, 2023 05:46am

• Policy
• Marketing authorization imminent for Obizur in Korea
• by Lee, Hye-Kyung Mar 17, 2023 05:46am

• Company
• Enhertu's petition subcommittee is announced
• by Eo, Yun-Ho Mar 17, 2023 05:46am

• Company
• MSD ‘Januvia’s NTTP impurity level is at low risk’
• by Jung, Sae-Im Mar 17, 2023 05:45am

• Product
• It is difficult to solve the problem of expensive generics
• by Mar 16, 2023 05:46am